National Institute on Drug Abuse; Notice of Meeting, 14597-14598 [07-1513]
Download as PDF
<![CDATA[
Federal Register / Vol. 72, No. 59 / Wednesday, March 28, 2007 / Notices
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.375, Minority Biomedical
Research Support; 93.821, Cell Biology and
Biophysics Research; 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.862, Genetics and
Developmental Biology Research; 93.88,
Minority Access to Research Careers; 93.96,
Special Minority Initiatives, National
Institutes of Health, HHS)
Dated: March 20, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–1509 Filed 3–27–07; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Biomedical
Imaging and Bioengineering; Notice of
Closed Meeting
sroberts on PROD1PC70 with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Biomedical Imaging and Bioengineering
Special Emphasis Panel, ZEB1 OSR–C (A1) S
(LRP).
Date: May 18, 2007.
Time: 2 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Suite 220 small conference room,
Bethesda, MD 20892, (Telephone Conference
Call).
Contact Person: Prabha L. Atreya, PhD,
Scientific Review Administrator, Office of
Scientific Review, National Institute of
Biomedical Imaging and Bioengineering,
Bethesda, MD 20892; (301) 496–8633,
atreyapr@mail.nih.gov.
VerDate Aug<31>2005
17:09 Mar 27, 2007
Jkt 211001
Dated: May 20, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–1510 Filed 3–27–07; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of a meeting of the
National Commission on Digestive
Diseases.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
Name of Committee: National Commission
on Digestive Diseases.
Date: June 18–19, 2007.
Time: 9 a.m. to 12 p.m.
Agenda: Introductions; updates from
Working Groups; Commission timeline and
next steps; and general discussion. Preregistration is required. Instructions will be
available on the Commission’s Web site at
https://NCDD.niddk.nih.gov.
Place: Sheraton Crystal City, 1800 Jefferson
Davis Highway (Rt. 1), Grand Ballroom C,
Arlington, VA 22202.
Contact Person: Stephen P James, MD,
Director, Division of Digestive Diseases &
Nutrition, National Institute of Diabetes and
Digestive and Kidney Diseases, NIH, 6707
Democracy Blvd., Rm 677, Bethesda, MD
20892–5450, 301–594–7680,
natlcommdd@mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: March 21, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–1512 Filed 3–27–07; 8:45 am]
BILLING CODE 4140–01–M
PO 00000
Frm 00083
Fmt 4703
Sfmt 4703
14597
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of a meeting of the
National Advisory Council on Drug
Abuse.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need assistance, such as sign language
interpretation or other reasonable
accommodations, should notify the
Contact Person listed below in advance
of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Council on Drug Abuse.
Date: May 15–16, 2007.
Closed: May 15, 2007, 3 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852.
Open: May 16, 2007, 8:30 a.m. to 1 p.m.
Agenda: This portion of the meeting will
be open to the public for announcements and
reports of administrative, legislative and
program developments in the drug abuse
field.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852.
Contact Person: Teresa Levitin, PhD,
Director, Office of Extramural Affairs,
National Institute on Drug Abuse, NIH,
DHHS, Room 220, MSC 8401, 6101 Executive
Boulevard, Bethesda, MD 20892–8401, (301)
443–2755.
Any member of the public interested in
presenting oral comments to the committee
may notify the Contact Person listed on this
notice at least 10 days in advance of the
meeting. Interested individuals and
representatives of organizations may submit
a letter of intent, a brief description of the
organization represented, and a short
description of the oral presentation. Only one
representative of an organization may be
allowed to present oral comments and if
accepted by the committee, presentations
may be limited to five minutes. Both printed
E:\FR\FM\28MRN1.SGM
28MRN1
14598
Federal Register / Vol. 72, No. 59 / Wednesday, March 28, 2007 / Notices
and electronic copies are requested for the
record. In addition, any interested person
may file written comments with the
committee by forwarding their statement to
the Contact Person listed on this notice. The
statement should include the name, address,
telephone number and when applicable, the
business or professional affiliation of the
interested person.
Information is also available on the
Institute’s/Center’s home page: https://
www.drugabuse.gov/NACDA/
NACDAHome.html, where an agenda and
any additional information for the meeting
will be posted when available.
Based Core Competency Training for
Coalitions.
Date: April 27, 2007.
Time: 9:30 a.m. to 11:30 a.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, 6101
Execution Boulevard, Rockville, MD 20852,
(Telephone Conference Call).
Contact Person: Nadine Rogers, Health
Scientist Administrator, Office of Extramural
Affairs, National Institute on Drug Abuse,
NIH, DHHS, Room 220, MSC 8401, 6101
Executive Boulevard, Bethesda, MD 20892–
8401, (301) 402–2105, roersn2@nida.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: March 21, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–1513 Filed 3–27–07; 8:45 am]
(Catalogue of Federal Domestic Assistance
Program Nos. 92.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: March 21, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–1514 Filed 3–27–07; 8:45 am]
BILLING CODE 4140–01–M
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
National Institute of Biomedical
Imaging and Bioengineering; Notice of
Meeting
sroberts on PROD1PC70 with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associate with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Drug Abuse Special Emphasis Panel, Clinical
Trails Network Services.
Date: April 18–19, 2007.
Time: 9 a.m. to 5 p.m.
Agenda: To review and evaluate grant
proposals.
Place: Courtyard by Marriott Rockville,
2500 Research Boulevard, Rockville, MD
20850.
Contact Person: Lyle Furr, Contract Review
Specialist, Office of Extramural Affairs,
National Institute on Drug Abuse, NIH,
DHHS, Room 220, MSC 8401, 6101 Executive
Boulevard, Bethesda, MD 20892–8401, (301)
435–1439, if33c.nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel, Web-
VerDate Aug<31>2005
17:09 Mar 27, 2007
Jkt 211001
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of a meeting of the
National Advisory Council for
Biomedical Imaging and Bioengineering.
The meeting will be open to the
public as indicated below with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Council for Biomedical Imaging and
Bioengineering, May Council.
Date: May 16, 2007.
Time: 8:30 a.m. to 1:15 p.m.
PO 00000
Frm 00084
Fmt 4703
Sfmt 4703
Agenda: Report from the Institute Director,
other Institute Staff and presentations of
working group reports.
Place: Bethesda Marriott Suites, 6711
Democracy Boulevard, Bethesda, MD 20817.
Closed: 1:15 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott Suites, 6711
Democracy Boulevard, Bethesda, MD 20817.
Contact Person: Anthony Demsey, PhD,
Director, Office of Extramural Policy,
National Institute of Biomedical Imaging and
Bioengineering, 6701 Democracy Blvd.,
Room 241, Bethesda, MD 20892.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: https://
www.nibib1.nih.gov/about/NACBIB/
NACBIB.htm, where an agency and any
additional information for the meeting will
be posted when applicable.
Dated: March 21, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–1517 Filed 3–27–07; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel Ancillary Studies to
Major Ongoing NIDDK and NHLBI Clinical
Research Studies PAR–06–216.
Date: April 9, 2007.
Time: 11 a.m. to 1 p.m.
Agenda: To review and evaluate grant
applications.
E:\FR\FM\28MRN1.SGM
28MRN1
]]>Agencies
[Federal Register Volume 72, Number 59 (Wednesday, March 28, 2007)]
[Notices]
[Pages 14597-14598]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 07-1513]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of
the National Advisory Council on Drug Abuse.
The meeting will be open to the public as indicated below, with
attendance limited to space available. Individuals who plan to attend
and need assistance, such as sign language interpretation or other
reasonable accommodations, should notify the Contact Person listed
below in advance of the meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Advisory Council on Drug Abuse.
Date: May 15-16, 2007.
Closed: May 15, 2007, 3 p.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852.
Open: May 16, 2007, 8:30 a.m. to 1 p.m.
Agenda: This portion of the meeting will be open to the public
for announcements and reports of administrative, legislative and
program developments in the drug abuse field.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852.
Contact Person: Teresa Levitin, PhD, Director, Office of
Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS,
Room 220, MSC 8401, 6101 Executive Boulevard, Bethesda, MD 20892-
8401, (301) 443-2755.
Any member of the public interested in presenting oral comments
to the committee may notify the Contact Person listed on this notice
at least 10 days in advance of the meeting. Interested individuals
and representatives of organizations may submit a letter of intent,
a brief description of the organization represented, and a short
description of the oral presentation. Only one representative of an
organization may be allowed to present oral comments and if accepted
by the committee, presentations may be limited to five minutes. Both
printed
[[Page 14598]]
and electronic copies are requested for the record. In addition, any
interested person may file written comments with the committee by
forwarding their statement to the Contact Person listed on this
notice. The statement should include the name, address, telephone
number and when applicable, the business or professional affiliation
of the interested person.
Information is also available on the Institute's/Center's home
page: https://www.drugabuse.gov/NACDA/NACDAHome.html, where an agenda
and any additional information for the meeting will be posted when
available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.279, Drug
Abuse and Addiction Research Programs, National Institutes of
Health, HHS)
Dated: March 21, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 07-1513 Filed 3-27-07; 8:45 am]
BILLING CODE 4140-01-M
